Last reviewed · How we verify
Cimetidine plus CHF5993 pMDI — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
Cimetidine plus CHF5993 pMDI (Cimetidine plus CHF5993 pMDI) — Chiesi Farmaceutici S.p.A..
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Cimetidine plus CHF5993 pMDI TARGET | Cimetidine plus CHF5993 pMDI | Chiesi Farmaceutici S.p.A. | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Cimetidine plus CHF5993 pMDI CI watch — RSS
- Cimetidine plus CHF5993 pMDI CI watch — Atom
- Cimetidine plus CHF5993 pMDI CI watch — JSON
- Cimetidine plus CHF5993 pMDI alone — RSS
Cite this brief
Drug Landscape (2026). Cimetidine plus CHF5993 pMDI — Competitive Intelligence Brief. https://druglandscape.com/ci/cimetidine-plus-chf5993-pmdi. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab